Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least squares (OLS)...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population-based analysis of the cost of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation.

Revista espanola de cardiologia (English ed.)·2025
Same author

Clinical Outcome and Costs Based on the Degree of Vitamin K Antagonist Control for Non-Valvular Atrial Fibrillation.

Journal of clinical medicine·2025
Same author

Actions to Improve the Secondary Prevention of Fragility Fractures in Women with Postmenopausal Osteoporosis: A Social Return on Investment (SROI) Study.

ClinicoEconomics and outcomes research : CEOR·2024
Same author

Measuring population health using health expectancy estimates from morbidity and mortality databases.

PloS one·2024
Same author

Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019.

Pharmaceuticals (Basel, Switzerland)·2021
Same author

Mental Illness Inequalities by Multimorbidity, Use of Health Resources and Socio-Economic Status in an Aging Society.

International journal of environmental research and public health·2021

Related Experiment Video

Updated: Jul 15, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Predictability of drug expenditures: an application using morbidity data.

Manuel García-Goñi1, Pere Ibern

  • 1Departamento de Economía Aplicada II, Universidad Complutense de Madrid, Madrid, Spain. mggoni@ccee.ucm.es

Health Economics
|April 12, 2007
PubMed
Summary

Predicting pharmaceutical expenditure is crucial. This study uses Clinical Risk Groups (CRGs) and demographic data to accurately forecast drug costs, offering insights for healthcare policy and premium setting.

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Related Experiment Videos

Last Updated: Jul 15, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Area of Science:

  • Health Economics
  • Healthcare Management
  • Pharmaceutical Policy

Background:

  • Pharmaceutical expenditure growth presents challenges for policymakers and healthcare managers.
  • Accurate prediction of drug costs is essential for financial planning and resource allocation in healthcare systems.

Purpose of the Study:

  • To explore and evaluate different predictive models for estimating future pharmaceutical expenditure.
  • To assess the utility of Clinical Risk Groups (CRGs) as risk adjusters in predicting drug costs.
  • To provide an alternative method for drug expenditure estimation with high predictive power.

Main Methods:

  • Utilized demographic and morbidity data from an integrated healthcare delivery organization in Catalonia (2002-2003).
  • Employed Clinical Risk Groups (CRGs) to codify and group health encounters for morbidity information.
  • Estimated pharmaceutical costs using various model specifications with CRGs as risk adjusters.

Main Results:

  • Achieved high predictive power for drug expenditures, comparable to existing literature estimations.
  • Demonstrated the effectiveness of CRGs in risk adjustment for pharmaceutical cost prediction.
  • Identified specific model specifications that yield robust predictions.

Conclusions:

  • Clinical Risk Groups (CRGs) offer a viable and powerful tool for risk adjustment in predicting pharmaceutical expenditure.
  • The findings have significant implications for setting premiums for pharmaceutical benefits and informing healthcare policy.
  • This approach provides a reliable alternative for estimating drug expenditures, aiding financial management in healthcare organizations.